Altered polypeptides with increased half-life
AssigneeGenentech, Inc.
InventorsLeonard G. Presta, Bradley R. Snedecor
Life of this patent
Estimating the term…
Abstract
Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
Claims23
A nucleic acid encoding a modified polypeptide with an improved in vivo half-life, said modified polypeptide comprising an Ig constant domain or an Ig-like constant domain and a salvage receptor binding epitope within said Ig constant domain or Ig-like constant domain, wherein said epitope is absent from the unmodified polypeptide, wherein said salvage receptor epitope is taken from two loops of the CH2 domain of an Fc region of an Ig molecule and wherein said polypeptide in modified form does not comprise an intact CH2 domain or an intact Ig Fc region.
A method for preparing a modified polypeptide variant having an increased in vivo half-life comprising:
- modifying a polypeptide such that said modified polypeptide comprises an Ig or Ig-like constant domain and a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG within the Ig or Ig-like constant domain, and which variant has a longer in vivo half-life than the unmodified polypeptide.
Dependencies are inferred from the claim text.